EGFR and non-small cell lung carcinoma: The results from this trial demonstrated prolonged PFS (25.5m vs 16.7m, HR 0.62) and OS (not reached vs. 36.7m, HR 0.75;41% maturity) benefit trend with the combination therapy as compared with osimertinib monotherapy in patients with EGFR-mutated advanced NSCLC.